3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
175
Neoplasm Metastasis
19
Breast Neoplasms
19
Prostatic Neoplasms, Castration-Resistant
17
Neoplasms
16
Metastatic Castration Resistant Prostate Cancer
8
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Colorectal Neoplasms
4
Castration-resistant Prostate Cancer
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Hepatocellular
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2
Interventions
Cisplatin
7
Etoposide
5
pembrolizumab
4
Topotecan
4
Pemetrexed
4
Gemcitabine
3
Carboplatin
3
belinostat
2
Temozolomide
2
RRx-001
2
Paclitaxel
2
vosaroxin
1
vinflunine
1
veliparib
1
taxane
1
sagopilone
1
sacituzumab govitecan
1
pomalidomide
1
lurtotecan
1
liposomal doxorubicin
1
etoposide phosphate
1
enzalutamide
1
bemiparin
1
belotecan
1
apalutamide
1
alvocidib
1
abiraterone
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Small Cell
×
enzalutamide
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts